Exploring newer cardioprotective strategies: ω-3 fatty acids in perspective

Matteo Nicola Dario Di Minno1; Elena Tremoli2; Antonella Tufano1; Anna Russolillo1; Roberta Lupoli1; Giovanni Di Minno1

1Department of Experimental and Clinical Medicine, “Federico II” University, Naples, Italy; 2Department of Pharmacological Sciences, Milan University, Milan, Italy

Summary
In the 1980s, observational retrospective studies showed an inverse relation between coronary heart disease (CHD) and consumption of fish containing fatty acids that belong to the omega (ω)-3 family. Large case-control studies and prospective intervention trials consistently showed that ω-3 fatty acids supplementation lowers fatal myocardial infarction (MI) and sudden cardiac death. By analysing the strengths of the results of individual studies and how the meta-analyses agree with them, putting together relevant backgrounds, and identifying open questions, the following findings/directions emerge. (i) Dietary and non-dietary intake of ω-3 fatty acids reduces overall mortality, mortality due to MI, and sudden death in patients with CHD; (ii) Fish oil consumption directly or indirectly affects cardiac electrophysiology. Fish oil reduces heart rate, a major risk factor for sudden death; (iii) Among patients with implantable cardioverter defibrillators, ω-3 fatty acids do not reduce the risk of ventricular tachycardia/ventricular fibrillation and may actually be pro-arrhythmic; (iv) The consumption of ω-3 fatty acids leads to a 10–33% net decrease of triglyceride levels. The effect is dose-dependent, larger in studies with higher mean baseline triglyceride levels, and consistent in different populations (healthy people, people with dyslipidaemia, diabetes, or known cardiovascular risk factors); (v) Outcomes for which a small beneficial effect ω-3 fatty acids is found include blood pressure (about 2 mmHg reduction), re-stenosis rates after coronary angioplasty (14% reduction), and exercise tolerance testing. Major experimental data provide strength (biological plausibility) for these findings, and define directions for newer clinical trials with ω-3 fatty acids.

Keywords
Prevention, acute myocardial infarction, nutrition

Introduction
Modern nutrition emphasises health benefits of eating sufficient levels of the very long chain polyunsaturated fatty acids that belong to the omega (ω)-3 family: eicosapentaenoic acid [EPA], docosahexaenoic acid [DHA], and α-linolenic acid [ALA]. Such bioactive compounds, whose predominant sources are fish and vegetable oils, are not convertible and have very different biochemical roles. Clinical data emphasise the efficacy of ω-3 fatty acids supplementation over and above the usual GISSI strategy (aspirin, beta-blockers, nitrate, ACE-inhibitors, statins) for the prevention of coronary heart disease (CHD) and ischaemic events in survivors of a myocardial infarction (MI) (1). However, in the therapeutic strategy of such patients, the additional benefits ω-3 fatty acids are presently poorly understood. By analysing the strengths of the findings and how the meta-analyses agree with the individuals reports on the prevention of CHD/sudden death by ω-3 fatty acids; putting together relevant backgrounds; examining the evidence and identifying inconsistencies and open questions of single studies, we report here that the utility of ω-3 fatty acids presently appears to be largely due to their triglyceride lowering capability and to their anti-arrhythmic benefits. We also report that, while the mechanism by which triglycerides promote atherogenicity may be difficult to separate from its synergistic effect with lipoprotein and other cardiovascular variables, the additional benefits of ω-3 fatty acids do not include the lowering of total or LDL cholesterol. Potential directions to be pursued in secondary care and post-MI patients are also discussed.

Methods
We have approached the issue of ω-3 fatty acids and their relevance in clinical practice, with emphasis on three comprehensively reviewed relevant issues. In all cases, a series of key terms has been identified for an appropriate search strategy:
• The actual strength of the evidence of the association of ω-3 fatty acids and prevention/treatment of coronary heart disease (CHD);
• The actual strength of the evidence of the association of ω-3 fatty acids and the prevention/treatment of (ventricular) arrhythmias;

Thrombosis and Haemostasis 104.4/2010
The biological plausibility and potential mechanisms of the benefits of ω-3 fatty acids use in cardioprotection (including prevention/treatment of CHD and of arrhythmias).

As to the latter issue, it has been thoroughly reviewed in a series of papers concerning antiarrhythmic/antifibrillatory effects of ω-3 fatty acids. As to the former issues, the analysis has been based on epidemiological and intervention studies published up to 2010.

Search strategy and evidence acquisition

Using the key terms of: ω-3 fatty acids, cardioprotection; ω-3 fatty acids, mechanisms; plasma/cellular ω-3 fatty acids, risk of CHD; ω-3 fatty acids, randomised clinical studies (RCTs); ω-3 fatty acids, prevention of CHD, observational studies; ω-3 fatty acids, prevention of CHD, retrospective studies; ω-3 fatty acids, primary prevention of CHD, RCTs; ω-3 fatty acids, secondary prevention of CHD, RCTs; ω-3 fatty acids, prevention of arrhythmias, patients with implantable cardioverter defibrillators (ICDs), RCTs; ω-3 fatty acids, prevention of cardiovascular death, meta-analyses of RCTs; we searched in the Medline and Cochrane databases as well as the trial register of the Cochrane group to identify studies published in the area up to March 2010. For an in-depth scrutiny of the information provided by the individual papers, their references were also critically reviewed. In each case and for each report, in addition to clinical relevance, emphasis has been put and the inherent potential limitations of the individual analyses. We have found the following evidence synthesis.

ω-3 fatty acids and prevention of CHD/ sudden death

Observational, retrospective studies

In the early 1960s and 1970s, dietary advice to prevent recurrence of CHD was inconclusive. This was likely to be due to the small (=500) number of subjects examined. Moreover, in these studies, attempts to lower plasma cholesterol levels in survivors of MI were based on diets lower in fats or with high polyunsatuated/saturated ratios. Excessive consumption of foods containing ω-3 fatty acids increases total fat intake. In view of this, the intake of saturated fats was decreased and that of unsaturated was increased. Thus, the study design and the sample size may have been inadequate to address the issue (1). In the 1980s, three retrospective studies (2–4) showed an inverse relation between fish consumption and CHD mortality. In parallel, fish fats containing EPA were shown to impair platelet aggregation and thromboxane formation, two major events in arterial thrombosis (5). The combined data fostered newer studies in the field.

Prospective (nested case-control) studies

A series of nested case-control studies showed an inverse association between low plasma/cellular EPA/DHA and risk of MI, sudden cardiac death, or total cardiovascular mortality (Table 1). A strong inverse correlation between fish consumption and total mortality as well as sudden death was first found in the Physicians’ Health Study (PHS) (6, 7). A total of 20,551 US male physicians 40 to 84 years of age and free of MI, cerebrovascular disease, and cancer at baseline were evaluated, after 11 years follow-up, for the incidence of sudden cardiac death (6). Dietary fish intake was associated with a reduced risk of total mortality as well as of sudden death, with an apparent threshold effect at a consumption level of one fish meal per week (p for trend=0.03). For men who consumed fish at least once per week, the relative risk (RR) of sudden death was 0.48 (p=0.04) compared with men who consumed fish less than monthly. Neither dietary fish consumption nor ω-3 fatty acid intake was associated with a reduced risk of total MI, non-sudden cardiac death, or total cardiovascular mortality. The extended follow-up (17 years) of the study (7) showed that ω-3 fatty acids found in fish are strongly associated with a reduced risk of sudden death among men without evidence of prior cardiovascular disease (CVD). Baseline blood levels of long-chain ω-3 fatty acids were inversely related to the risk of sudden death both before (p for trend=0.004) and after (p for trend = 0.007) adjustment for potential confounders.

In the Nurses Health Study (NHS) (8), a cohort study in 84,688 female nurses aged 34 to 59 years and free from CVD and cancer at baseline (1980), dietary consumption and follow-up data were collected with validated questionnaires (24). Compared with women who seldom ate fish (<1 serving/month), those with a higher intake of fish had a lower risk of CHD. Similarly, women with a higher intake of ω-3 fatty acids had a lower risk of CHD (p<0.001 for trend) across quintiles of intake. For fish intake and ω-3 fatty acids, the inverse association appeared to be stronger for CHD deaths than for non-fatal MI. A higher consumption of fish and ω-3 fatty acids was associated with a 30% reduction in the risk of major coronary events. This reduction increased when only fatal events (coronary deaths) were considered.

Employing dietary interviews and local food tables, Oomen et al. (9) have evaluated the association between total, lean, and fatty fish consumption and the risk of CHD mortality in 1,088 Finnish, 1,097 Italian, and 553 Dutch men participating in the Seven Countries Study, who were aged 50–69 years and free of CHD. After 20 years of follow-up, 242 (22.2%) men in Finland, 116 (10.6%) men in Italy, and 105 (19.0%) men in the Netherlands had died of CHD. After adjustment for confounders, while lean fish consumption was not associated with CHD mortality in any of the three Countries, fatty fish was associated with lower CHD mortality, pooled RR for fatty fish consumers being 0.66.

The association of plasma phospholipid concentrations of DHA, EPA, and ALA as biomarkers of intake with the risk of incident fatal CHD and incident non-fatal MI in older adults was investigated in the Cardiovascular Health Study, a cohort study of adults aged ≥65 years (10). Plasma phospholipid concentrations of
ω-3 fatty acids and coronary heart disease

### Table 1: ω-3 fatty acids and cardioprotection: nested case-control studies in prevention of CHD/sudden death.

<table>
<thead>
<tr>
<th>Author (ref)</th>
<th>Study description</th>
<th>Results</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albert CM (6)</td>
<td>Study description: The Physicians’ Health Study (PHS) evaluated the incidence of sudden cardiac death (death within 1 hour of symptom onset) in a total of 20,551 US male physicians 40 to 84 years of age, free of MI, cerebrovascular disease, and cancer at baseline, who completed a semiquantitative food frequency questionnaire on fish consumption. Results: There were 133 sudden deaths over the course of the study. After controlling for age, randomised aspirin and β-carotene assignment and coronary risk factors, dietary fish intake was associated with a reduced risk of sudden death, with an apparent threshold effect at a consumption level of one fish meal per week (p for trend=0.03). For men who consumed fish at least once per week, the multivariate relative risk (RR) of sudden death was 0.48 (95% CI, 0.24–0.96; p=0.04) compared with men who consumed fish less than monthly. Estimated dietary ω-3 fatty acid intake from seafood was also associated with a reduced risk of sudden death, without a significant trend across increasing categories of intake. Neither dietary fish consumption nor ω-3 fatty acid intake was associated with a reduced risk of total MI, non-sudden cardiac death, or total cardiovascular mortality and total mortality.</td>
<td>Consumption of fish at least once per week may reduce the risk of sudden cardiac death in men.</td>
<td></td>
</tr>
<tr>
<td>Hu FB (8)</td>
<td>Study description: Incident non-fatal myocardial infarction (MI) and coronary heart disease (CHD) deaths were evaluated in the Nurses Health Study (NHS), a cohort study in 84,688 female nurses aged 34 to 59 years, free from cardiovascular disease and cancer at baseline (1980), in whom dietary consumption and follow-up data were compared from validated questionnaires. Results: During 16 years of follow-up, there were 1513 incident cases of CHD (484 CHD deaths and 1,029 non-fatal MIs). Compared with women who seldom ate fish (&lt;1 per month), those with a higher intake of fish had a lower risk of CHD. After adjustment for age, smoking, and other cardiovascular risk factors, the RRs of CHD were 0.79 (95% CI, 0.64–0.97) for fish consumption 1-3 times per month, 0.71 (95% CI, 0.58–0.87) for once per week, 0.69 (95% CI, 0.55–0.88) for 2-4 times per week, and 0.66 (95% CI, 0.50–0.89) for five or more times per week (p for trend =0.001). Women with a higher intake of ω-3 fatty acids had a lower risk of CHD, with RRs of 1.0, 0.93, 0.78, 0.68, and 0.67 (p&lt;0.001 for trend) across quintiles of intake. For fish intake and ω-3 fatty acids, the inverse association was stronger for CHD deaths (multivariate RR for fish consumption five times per week, 0.55 [95% CI, 0.33–0.90] for CHD deaths vs 0.73 [0.51–1.04]) than for non-fatal MI.</td>
<td>A higher consumption of fish and ω-3 fatty acids is associated with a 30% reduction in the risk of major coronary events especially in people at high risk of CHD.</td>
<td></td>
</tr>
<tr>
<td>Oomen et al. (9)</td>
<td>Study description: Analysis of the association between total, lean, and fatty fish consumption (dietary interviews) and the risk of CHD mortality in 1,088 Finnish, 1,097 Italian, and 553 Dutch men participants in the Seven Countries Study who were aged 50–69 years and free of CHD around 1970. Results: After 20 years of follow-up, 242 [22.2%] men in Finland, 116 [10.6%] men in Italy, and 105 [19.0%] men in the Netherlands had died of CHD. Cox proportional hazards analysis showed no association between total fish consumption and CHD mortality. After adjustments for age, body mass index, smoking, energy intake, and relevant dietary variables, the pooled RR for the highest quintile of total fish consumption compared with no fish consumption in the three countries was 1.08 (95% CI: 0.76, 1.53). Lean fish consumption was not associated with CHD mortality in any country. In contrast, fatty fish compared with non-fatty-fish consumption was associated with lower CHD mortality; the adjusted pooled RR for fatty fish consumers was 0.66 (95% CI: 0.49, 0.90).</td>
<td>Fatty fish, rich in ω-3 polynsaturated fatty acids, protects from CHD mortality.</td>
<td></td>
</tr>
<tr>
<td>Lemaitre RN (10)</td>
<td>Study description: The risk of incident fatal ischaemic heart disease and incident nonfatal MI in older adults was investigated among participants to the Cardiovascular Health Study, a cohort study of adults aged ≥65 years. Such risk was related with plasma phospholipid concentrations of DHA, EPA, and α-linolenic acid. Plasma phospholipid concentrations of ω-3 polynsaturated fatty acids were measured in blood samples drawn approximately two years before the event. Results: Cases experienced incident fatal MI, ischaemic heart disease death (n=54) and incident non-fatal MI (n=125). Matched controls were randomly selected (n = 179). A higher concentration of combined DHA and EPA was associated with a lower risk of fatal ischaemic heart disease, and a higher concentration of α-linolenic acid with a tendency to lower risk, after adjustment for risk factors (OR: 0.32 (95% CI: 0.13, 0.78; p = 0.01) and 0.52 (0.24, 1.15; p = 0.1), respectively). Conclusion: Higher combined dietary intake of DHA and EPA, and possibly ω-linolenic acid, may lower the risk of fatal ischaemic heart disease in older adults.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Simon JA (11)</td>
<td>Study description: In the Usual Care group of the Multiple Risk Factor Intervention Trial (MRFIT), DHA in plasma phospholipids was measured in stored serum samples from 94 men who subsequently developed CHD and in 94 matched controls who did not. Results: In a multivariate model controlled for the ratio of HDL to LDL cholesterol, the concentration of DHA was inversely associated with CHD risk (OR: 0.57; 95% CI: 0.36, 0.90).</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ω-3 fatty acids were measured in blood samples drawn approximately two years before the event. After adjustment for risk factors, a higher concentration of combined DHA and EPA was associated with a lower risk of fatal ischaemic heart disease (p = 0.01). Since no association was found with non-fatal MI, the conclusion was that the data are consistent with possible antiarrhythmic effects of these fatty acids.

Finally, in the Usual Care group of the Multiple Risk Factor Intervention Trial, DHA in plasma phospholipids was measured in stored serum samples from 94 men who subsequently developed CHD (11). The concentration of DHA was inversely associated with CHD risk (odds ratio [OR]: 0.57; 95% confidence interval [CI]: 0.36, 0.90).

**RCTs in secondary prevention of CHD/sudden death**

Prospective studies consistently showed that ω-3 fatty acids supplementation lowers the risk of total MI, sudden cardiac death, or total cardiovascular mortality. (Table 2).

The **Diet and Reinforcement Trial (DART)** (12) randomised 2,033 men, who had recovered from a MI, to advice to eat at least two portions (200–400 g) of oily fish per week, to reduce their total fat and saturated fat intake, or to increase their intake of cereal fibre. The equivalent weekly consumption of EPA was about 2.5 g (300 g of oily fish). At two years, about 22% of patients who could not tolerate the recommended amount of fish, took fish oils as a partial or total substitute. At this time, when compared with other groups, about 30% fewer people in the fish advice group died, a reduction that was due to less CHD deaths (7.7% vs. 11.4%). There was no significant reduction in CHD events overall (CHD death or non-fatal MI) probably because the reduction in CHD death was counterbalanced by an increase in non-fatal MI.

The **Lyon Heart trial study** was a prospective, randomised single-blinded multicentre trial whose primary endpoints were death and non-fatal MI (13). Of the 600 survivors enlisted, half adopted a prudent diet and as many adopted a Mediterranean-type of diet, with more bread, vegetables, fish, fresh fruit and olive oil (or margarine enriched in ALA for subjects who did not like olive oil). At the two-year follow-up, there were 16 cardiovascular deaths in the control group and three in the experimental one. Similar to the DART study, the beneficial effect of this diet occurred early after randomisation and was not associated with changes in plasma cholesterol or HDL-cholesterol levels. After correction for other factors, a surprisingly high (76%) reduction in the risk of cardiac death was found during the observation period. The protective effect of the experimental diet was associated with enhanced plasma levels of EPA and ALA. In keeping with this, arachidonic acid was significantly reduced in subjects who had received the experimental diet. However, variables other than EPA were affected by the Mediterranean type of diet. The antioxidant vitamin E, was significantly increased while granulocyte count was lowered.

The **Gisii Prevenzione trial** (14) was a prospective, multicentre, open labelled trial, in which 11,324 recent (<3 months) survivors of a first MI, were randomly assigned to receive, in addition to the usual GISSI strategy (aspirin, beta-blockers, nitrate, ACE-inhibitors, statins), a supplementation of ω-3 fatty acids (1 g/day corresponding to 850 mg of a mixture of EPA+ DHA in a 1:1.4 ratio), vitamin E (300 mg/day), or the combination of ω-3 fatty acids + vitamin E. While the treatment with vitamin E was not effective as to event-free survival (p = 0.07), the treatment with ω-3 fatty acids significantly reduced the risk of new ischaemic events (p = 0.009). When the data were stratified as to individual endpoints, cardiovascular death (-30%), CHD death (-35%), total death (-20%) and sudden death (-45%) were all significantly reduced by the supplementation. Similar to the DART and the Lyon Studies, the beneficial effect of the supplementation occurred early after randomisation (3 months for total mortality and 4 months for sudden death) (15). As to the prevention of sudden death, it could be also documented in high-risk individuals such as those with systolic dysfunction (16). In 9,630 such patients, left ventricular systolic function was monitored by echocardiography (16). ω-3 fatty acids treatment reduced significantly the total mortality (24%, p = 0.02) in those with ventricular systolic dysfunction (ejection fraction <40%), and non significantly (19%) in those without ventricular systolic dysfunction (ejection fraction >50). In particular, patients with ejection fractions <40%, had a four-fold greater benefit from ω-3 fatty acids treatment in the reduction of sudden death compared to those with ejection fractions >50%.

The **DART-2 trial** (17, 18), included 3,114 men with stable angina and showed an excess of sudden and total cardiac deaths in these subjects. The excess was maximal in participants taking fish oil capsules rather than eating oily fish. This trial was described as ‘well designed but sub-optimally conducted or reported’ (19). Due to lack of funding, it was stopped midway during the trial, and it was unclear if the participants continued to adhere to the advice to increase their fish consumption or to take their fish oil supplements.

The objective of the **Nilsen study** (20) was to evaluate the effect of a high-dose ethylester concentrate of ω-3 fatty acids administered early after an acute MI. No significant difference in prognosis was observed between groups for single or combined cardiac events. The authors concluded that no clinical benefit of a high-dose concentrate of ω-3 fatty acids compared with corn oil was found despite a favorable effect on serum lipids. The lack of benefit in this setting has been thought to be due to the high background intake of fish oils in the Norwegian study participants, which could have masked the treatment effects.

Data from the **JELIS Study** (21) do not support this formulation. In the latter (21), in 18,645 patients with a total cholesterol of 6.5 mM or greater, recruited from local physicians throughout Japan, the hypothesis was tested that long-term use of EPA is effective for prevention of major coronary events. Out of them 14,981 were subject to primary prevention and 3,664 to secondary prevention. This study population was likely to have high levels of serum EPA because of the high fish consumption in the Japanese population (22). The patients were randomly assigned to receive either 1,800 mg of EPA daily plus statin (EPA group; n = 9,326) or statin only (controls; n = 9,319). At mean follow-up of 4.6 years, the authors documented the primary endpoint in 262 (2.8%) patients.
in the EPA group and in 324 (3.5%). Post-treatment LDL cholesterol concentrations decreased by 25%, in both groups. Unstable angina and non-fatal coronary events (including non-fatal MI, unstable angina, angioplasty, stenting, or coronary artery bypass) were also significantly reduced in the EPA group. Sudden cardiac death and coronary death did not differ between groups.

Heart failure (HF), a major cause of morbidity and mortality in the Western Countries, is a major public health concern. Being
marked by a rapid progression (impairment of quality of life, frequent hospital admissions etc.), its prognosis is worse than that of some cancers. β-blockers, ACE inhibitors, diuretics, digitalis, and spironolactone, can delay or even prevent the progression of HF (1). Whether, on top of such treatments, ω-3 fatty acids would improve mortality and morbidity among patients with chronic HF (NYHA class II–IV, of any cause and with any level of left ventricular systolic function), has been addressed in GISSI HF trial (23, 24). Long-term administration (3.9 years of follow-up) of 1 g/day ω-3 fatty acids to a large population of patients with HF (3,494 vs. 3,481 randomised to placebo), all receiving ACE-inhibitors, β-blockers, diuretics, digitalis, and spironolactone, was effective in reducing all-cause mortality (p-value 0.041), and hospitalisations for cardiovascular reasons (p-value 0.009). Compared to the placebo arm, the ω-3 fatty acids group resulted in a 1.8% absolute reduction in all-cause mortality and in 2.3% reduction in mortality or admission for cardiovascular reasons. A similar benefit was not seen in the arm randomised to statin therapy (24).

ω-3 fatty acids Supplementation and prevention of arrhythmias

The results of the GISSI Prevenzione and those of the PHS, supported the idea that ω-3 fatty acids prevent sudden death by reduc-
ω-3 fatty acids and coronary heart disease

Table 3: ω-3 fatty acids and cardioprotection: RCTs in patients with implantable cardioverter defibrillators (ICDs).

| Author (ref) | Study description | Study description: To test the possibility that long-chain ω-3 fatty acids may prevent potentially fatal ventricular arrhythmias in high-risk patients, 402 patients with ICDs were randomly assigned to double-blind treatment with either a fish oil or an olive oil daily supplement for 12 months. The primary end point, time to first ICD event for ventricular tachycardia or fibrillation (VT or VF) confirmed by stored electrograms or death from any cause, was analysed by intention to treat. Secondary analyses were performed for "probable" ventricular arrhythmias, "on-treatment" analyses for all subjects who had taken any of their oil supplements, and "on-treatment" analyses only of those who were on treatment for at least 11 months.

Results: Compliance with double-blind treatment was similar in the two groups; however, the non-compliance rate was high (35% of all enrollees). In the primary analysis, assignment to treatment with the fish oil supplement showed a trend toward a prolonged time to the first ICD event (VT or VF) or of death from any cause (risk reduction of 28%; p = 0.057). When treatments for probable episodes of VT or VF were included, the risk reduction became significant at 31%; p = 0.033. For those who stayed on protocol for at least 11 months, the anti-arrhythmic benefit of fish oil was improved for those with confirmed events (risk reduction of 38%; p = 0.034).

Conclusion: For individuals at high risk of fatal ventricular arrhythmias, a regular daily ingestion of fish oil fatty acids may reduce potentially fatal ventricular arrhythmias.

Leaf A (27) FAAT

Raitt MH (28) SEATTLE

Study description: Randomised, double-blind, placebo-controlled trial performed at six US medical centers, with enrollment from February 1999 until January 2003, to determine whether ω-3 fatty acids have beneficial antiarrhythmic effects in patients with a history of sustained VT or VF. Two hundred patients with an ICD and a recent episode of sustained VT or VF were randomly assigned to receive fish oil, 1.8 g/day, 72% ω-3 fatty acids, or placebo and were followed up for a median of 718 days (range, 20–828 days). Time to first episode of ICD treatment for VT/VF, changes in red blood cell concentrations of ω-3 fatty acids, frequency of recurrent VT/VF events, and predetermined subgroup analyses were determined.

Results: Patients randomised to receive fish oil had an increase in the mean % of ω-3 fatty acids in red blood cell membranes (from 4.7% to 8.3%, p < 0.001), with no change observed in patients receiving placebo. At six, 12, and 24 months, 46% (SE, 5%), 51% (5%), and 65% (5%) of patients randomised to receive fish oil had ICD therapy for VT/VF compared with 36% (5%), 41% (5%), and 59% (5%) for patients randomised to receive placebo (p = 0.19). In the subset of 133 patients whose qualifying arrhythmia was VT, 61% (SE, 6%), 66% (6%), and 79% (6%) of patients in the fish oil group had VT/VF at six, 12, and 24 months compared with 37% (6%), 43% (6%), and 65% (6%) of patients in the control group (p = 0.007). Recurrent VT/VF events were more common in patients randomised to receive fish oil (p < 0.001).

Conclusion: Among patients with a recent episode of sustained ventricular arrhythmia and an ICD, fish oil supplementation does not reduce the risk of VT/VF.

Brouwer IA (29) SOFA

Study description: Randomised, parallel, placebo-controlled, double-blind trial conducted at 26 cardiology clinics across Europe to study the effect of supplemental fish oil vs. placebo on ventricular tachyarrhythmia or death. A total of 546 patients with ICDs and prior documented malignant VT or VF were enrolled between October 2001 and August 2004. Patients were randomly assigned to receive 2 g/day of fish oil (n = 273) or placebo (n = 273) for a median period of 356 days (range, 14–379 days).

Results: The primary end point occurred in 81 (30%) patients taking fish oil vs. 90 (33%) patients taking placebo (hazard ratio [HR], 0.86; 95% CI, 0.64–1.16; p = 0.33). In prespecified subgroup analyses, the HR was 0.91 (95% CI, 0.66–1.26) for fish oil vs. placebo in the 411 patients who had experienced VT in the year prior to the study, and 0.76 (95% CI, 0.52–1.11) for 332 patients with prior MIs.

Conclusion: No strong protective effect of intake of ω-3 fatty acids from fish oil against ventricular arrhythmia in patients with ICDs is present in this report.
In view of this, three double-blind, randomised intervention studies in patients with implantable cardioverter defibrillators (ICDs) investigated the direct effects of fish oil on ventricular tachyarrhythmia (27–29) (►Table 3). These studies have been reviewed in detail (30).

A total of 402 patients with ICDs were randomly assigned to a double-blind treatment with either a fish oil or an olive oil daily supplement for 12 months in the FAAT trial (27). At the end of the study, in both treatment groups, the number of patients that discontinued their prescribed supplements was high (35% of all en-

<table>
<thead>
<tr>
<th>Author (ref)</th>
<th>Study description/results/conclusion/comments</th>
</tr>
</thead>
</table>
| Bucher et al. (31) | Study description: By evaluating dietary and non-dietary (supplemental) intake of ω-3 polyunsaturated fats of acids and CHD, 11 trials, published between 1966 and 1999, that included 7,951 patients in the intervention and 7,855 patients in the control groups were identified.

Results: The risk ratio of nonfatal MI in patients who were on ω-3 fatty acid-enriched diets, compared with control diets or placebo, was 0.8 (95% CI: 0.5 to 1.2, p=0.16; Breslow-Day test for heterogeneity, p=0.01), and the risk ratio of fatal MI was 0.7 (95% CI: 0.6 to 0.8, p<0.001; heterogeneity p>0.20). In 5 trials, sudden death was associated with a risk ratio of 0.7 (95% CI: 0.6 to 0.9, p<0.01; heterogeneity p=0.20), whereas the risk ratio of overall mortality was 0.8 (95% CI: 0.7 to 0.9, p<0.001; heterogeneity p>0.20). There was no difference in estimates between dietary and non-dietary interventions of ω-3 fatty acids for all investigated endpoints.

Conclusion: Dietary and non-dietary intake of ω-3 polyunsaturated fatty acids reduces overall mortality, mortality due to MI, and sudden death in patients with CHD.

Balk et al. (32) | Study description: Systematic review of the literature to assess the effect of the consumption of EPA, DHA, and ALA on various CVD risk factors and intermediate markers of CVD in healthy people, people with dyslipidaemia, diabetes, or known CVD. A total of 807 full text articles were screened and 123 studies that met inclusion criteria to address the key questions (i.e. studies in which the amount of fish or ω-3 fatty acid intake was quantified, less than 6 g of ω-3 fatty acid per day was consumed, and of at least 4 weeks’ duration) were analysed.

Results: ω-3 fatty acids showed a net decrease in triglycerides: 10–33%. The effect was dose-dependent, consistent in different populations, and was larger in studies with higher mean baseline triglyceride levels. The effect of ω-3 fatty acids on other serum lipids was weaker (up to a 6% increase in HDL). Outcomes for which a small beneficial effect was found with fish oil supplementation included blood pressure (about 2 mm Hg reduction), restenosis rates after coronary angioplasty (14% reduction), exercise tolerance testing, and heart rate variability. A direct relationships between dose of consumed ω-3 fatty acids and changes in measured levels of EPA+DHA, either as plasma or serum phospholipids, platelet phospholipids, or erythrocyte membrane phospholipids was found.

Conclusion: A large, consistent beneficial effect of ω-3 fatty acids was found only for triglyceride levels. Little or no effect of ω-3 fatty acids was found for a variety of other cardiovascular risk factors and markers of cardiovascular disease. The benefits of ω-3 fatty acids on reducing cardiovascular disease are not well explained by the fatty acids’ effects on the cardiovascular risk factors examined. A strong, linear association was found across studies between ω-3 fatty acid intake and tissue levels. Heterogeneity of treatment effect was common among studies across the outcomes evaluated.

Hopper et al. (33) | Study description: Meta-analysis to assess whether dietary or supplemental ω-3 fatty acids affect total mortality, cardiovascular events or cancers. RCTs and cohort studies were used. RCTs where ω-3 intake or advice was randomly allocated and unconfounded, and study duration was at least six months, were included. Cohorts were included where a cohort was followed up for at least six months and ω-3 intake estimated.

Results: Forty-eight randomised controlled trials (36,913 participants) and 41 cohort analyses were included. Pooled trial results did not show a reduction in the risk of total mortality or combined cardiovascular events in subjects taking additional ω-3 fats (with significant statistical heterogeneity). Sensitivity analysis, retaining only studies at low risk of bias, reduced heterogeneity and confirmed no significant effect of ω-3 fats. Restricting analysis to trials increasing fish-based ω-3 fats, or those increasing short chain ω-3s, did not suggest significant effects on mortality or cardiovascular events in either group. Subgroup analysis by dietary advice or supplementation, baseline risk of CVD or ω-3 dose suggested no clear effects of these factors on primary outcomes.

Conclusion: It is not clear whether dietary or supplemental ω-3 fats affect total mortality, combined cardiovascular events or cancers in people with, or at high risk of, cardiovascular disease or in the general population. There is no evidence to advise people to stop taking ω-3 fats. There is no clear evidence that ω-3 fats differ in effectiveness according to sources or dose.

He et al. (34) | Study description: Meta-analysis of cohort studies to examine the association between fish intake and CHD mortality. Studies were included if they provided a RR and corresponding 95% CI for CHD mortality in relation to fish consumption and to the frequency of fish intake. A database was developed on the basis of 11 eligible studies and 13 cohorts, including 222,364 individuals with an average 11.8 years of follow-up.

Results: Compared with those who never consumed fish or ate fish less than once per month, individuals with a higher intake of fish had lower CHD mortality. The multivariate RRs for CHD mortality were 0.89 (95% CI, 0.79 to 1.01) for fish intake 1-3 times per month, 0.85 (95% CI, 0.76 to 0.96) for once per week, 0.77 (95% CI, 0.66 to 0.89) for 2-4 times per week, and 0.62 (95% CI, 0.46 to 0.82) for five or more times per week. Each 20-g/day increase in fish intake was related to a 7% lower risk of CHD mortality (p for trend=0.03).

Conclusion: Fish consumption is inversely associated with fatal CHD. Mortality from CHD may be reduced by eating fish once per week or more.
### Table 4: Continued

<table>
<thead>
<tr>
<th>Author (ref)</th>
<th>Study description</th>
<th>Results</th>
<th>Conclusion</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Studer M (35)</td>
<td><strong>Systematic search of randomised controlled trials published up to June 2003, comparing any lipid-lowering intervention with placebo or usual diet, with respect to mortality.</strong> Outcome measures were mortality from all, cardiac, and non-cardiovascular causes. A total of 97 studies met eligibility criteria, with 137,140 individuals in intervention and 138,976 individuals in control groups.</td>
<td>Compared with control groups, RR for overall mortality were 0.87 for statins (95% CI, 0.81–0.94), 1.00 for fibrates (95% CI, 0.91–1.11), 0.84 for resins (95% CI, 0.66–1.08), 0.96 for niacin (95% CI, 0.86–1.08), 0.77 for ω-3 fatty acids (95% CI, 0.63–0.94), and 0.97 for diet (95% CI, 0.91–1.04). Compared with control groups, RR for cardiac mortality indicated benefit from statins (0.78; 95% CI, 0.72–0.84), resins (0.70; 95% CI, 0.50–0.99) and ω-3 fatty acids (0.68; 95% CI, 0.52–0.90). RR for non-cardiovascular mortality of any intervention indicated no association when compared with control groups, with the exception of fibrates (risk ratio, 1.13; 95% CI, 1.01–1.27).</td>
<td><strong>Conclusion:</strong> Statins and ω-3 fatty acids are the most favorable lipid-lowering interventions with reduced risks of overall and cardiac mortality.</td>
<td>- The high degree of heterogeneity across these studies precluded pooling of data. For breast cancer one significant estimate was for increased risk (RR, 1.47; 95% CI, 1.10–1.98) and three were for decreased risk (RR, 0.68–0.72); seven other estimates did not show a significant association. For colorectal cancer, there was one estimate of decreased risk (RR, 0.49; 95% CI, 0.27–0.79) and 17 estimates without association. For lung cancer one of the significant associations was for increased cancer risk (IRR, 3.0; 95% CI, 1.2–7.3), the other was for decreased risk (RR, 0.32; 95% CI, 0.13–0.76), and four other estimates were not significant. For prostate cancer, there was one estimate of decreased risk (RR, 0.43; 95% CI, 0.22–0.83) and one of increased risk (RR, 1.98; 95% CI, 1.34–2.93) for advanced prostate cancer; 15 other estimates did not show a significant association. The study that assessed skin cancer found an increased risk (RR, 1.13; 95% CI, 1.01–1.27).</td>
</tr>
</tbody>
</table>
been due to the lower levels of baseline ω-3 fatty acids in the erythrocytes (3.3% vs. 4.75%) of the patients they enrolled, as well as the lower fatty fish consumption. An alternative explanation may be attributed to the inclusion criteria of the two studies. Raitt et al. (28) enrolled patients who did not have a recent MI, whereas patients enrolled in FAAT were not excluded if they had a recent MI. Thus, the greater benefits of ω-3 fatty acid supplementation observed in FAAT may have been due to the presence of more ischemia-driven arrhythmia in the study population (30).

The Seattle trial was a randomised, double-blind, placebo-controlled trial performed at six US medical centers to determine whether ω-3 fatty acids have beneficial antiarrhythmic effects in patients with a history of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) (28). Two hundred patients with an ICD implanted because of a history of cardiac arrest, a history of sustained ventricular tachycardia or fibrillation during electrophysiologic studies and a recent episode of sustained VT or VF were randomly assigned to receive fish oil, 1.8 g/day, 72% ω-3 fatty acids, or placebo and were followed up for a median of 718 days (range, 20–828 days). According to Kaplan-Meier estimates, 28% of patients in the fish oil group reached the primary endpoint of VT/VF, or death compared to 39% of patients in the olive oil control group. At the end of 12 months, the ω-3 fatty acid group showed a trend toward a longer time to first ICD event (VT or VF) or death, with a risk reduction of 28% (p = 0.057) that disappeared at 6, 12, and 24 months observations. Recurrent VT/VF events were more common in patients randomised to receive fish oil (p<0.001). Thus, fish oil supplementation did not reduce the risk of VT/VF and was somehow proarrhythmic (28) among patients with a recent episode of sustained ventricular arrhythmia and an ICD.

The Study on ω-3 fatty acids and ventricular Arrhythmia (SOFA) (29) was a randomised, placebo-controlled, double-blind trial conducted at 26 cardiology clinics across Europe, to study the effect of supplemental fish oil vs. placebo on ventricular tachyarrhythmia or death. A total of 546 patients with ICDs and prior documented malignant VT or VF (at least one episode during the previous year) were enrolled. Half of the patients were randomly assigned to receive 2 g/day of fish oil (n = 273) containing 900 mg of ω-3 fatty acids for 12 months, as many to a placebo of high-oleic acid sunflower oil (n = 273) for a median period of 356 days (range, 14–379 days). The primary outcome was: incidence of recurrent spontaneous VT or VF and all-cause mortality. At one year, no significant difference in event-free survival was observed between treatment groups (70% vs. 67%, respectively). The primary end point occurred in 81 (30%) patients taking fish oil vs. 90 (33%) patients taking placebo (p = 0.33). The hazard ratio [HR], R was 0.91 (95% CI: 0.66–1.26) for fish oil vs. placebo in the 411 patients who had experienced VT in the year before the study, and 0.76 (95% CI: 0.52–1.11) for 332 patients with prior MIs. At variance with the findings by Raitt et al. (28), benefits of fish oil supplementation were most pronounced for patients with VT at entry.

One of the possible explanations for the discrepancies in results between these three studies may relate to differences in types of patients enrolled in each study (30). The mix of patients in SOFA (29) may have favored a positive result from fish oil therapy: 63% had a
recent MI in the latter, compared with 55% who had a prior, but not recent, MI in the study conducted by Raitt et al. (28) In addition, fewer patients enrolled in SOFA (29) had baseline VT (55%) compared with patients enrolled by Raitt et al. (28) (66%).

Raitt et al. (28) suggested that although sodium channel blockade by ω-3 fatty acids may be protective in acute ischaemia, it may be proarrhythmic in patients with premature ventricular contractions following an MI. Patients who were most adversely affected by ω-3 therapy in their study had a qualifying rhythm of VT, which would not have been an ischaemia-related arrhythmic event in the absence of an MI. They also stressed that, in the studies on ICD, patients with ventricular arrhythmias without the ischaemic background or recent MI had been included (28). Whether ω-3 fatty acids of cell membranes may exert opposite effects depending on the underlying mechanism of arrhythmia, and whether ω-3 fatty acids are mostly effective in arrhythmias with ischaemic backgrounds is open to discussion. The trials published to date in arrhythmias without the ischaemic background have either been inconclusive or underpowered (1).

**ω-3 fatty acids and cardioprotection:**

**Meta-analyses**

In the past years, there have been several major meta-analyses and systematic reviews of the literature summarising the effects of ω-3 fatty acids in cardiovascular prevention (31–40) (Table 4).

By evaluating dietary and non-dietary (supplemental) intake, Bucher et al. (31) have investigated the effects of ω-3 polyunsaturated fats of acids and CHD. The risk ratio of non-fatal MI in patients who were on ω-3 polyunsaturated fatty acid-enriched diets compared with control diets or placebo was 0.8 and the risk ratio of fatal MI was 0.7 (95% CI: 0.6 to 0.8; p <0.001; heterogeneity p >0.20). In five trials, sudden death was associated with a risk ratio of 0.7 whereas the risk ratio of overall mortality was 0.8 There was no difference in summary estimates between dietary and non-dietary interventions of ω-3 polyunsaturated fatty acids for all endpoints.

Balk et al. (32) performed a systematic review of the literature to assess the effect of consumption of EPA, DHA, and ALA on various CVD risk factors and intermediate markers of CVD in healthy people, people with dyslipidaemia, diabetes, or known CVD. Among the outcomes analysed, ω-3 fatty acids showed a consistently large, significant net decrease in triglycerides (10–33%). The effect was dose-dependent, consistent in different populations, and larger in studies with higher mean baseline triglyceride levels. The effect of ω-3 fatty acids on other serum lipids was weaker (up to a 6% increase in HDL). Outcomes for which a small beneficial effect was found with fish oil supplementation included blood pressure (about 2 mm Hg reduction), re-stenosis rates after coronary angioplasty (14% reduction), exercise tolerance testing, and heart rate variability. For other evaluated outcomes, including measures of glucose tolerance, the effects of ω-3 fatty acids were either small or inconsistent across studies. Across studies, a direct relationship between dose of consumed ω-3 fatty acids and changes in measured levels of EPA+DHA was found. The correlation between dose and change in level appears to be fairly uniform, 1 g supplementation of EPA and/or DHA corresponding to approximately a 1% increase in EPA+DHA level. They also reported that the benefits of ω-3 fatty acids on reducing cardiovascular disease are not well explained by the fatty acids’ effects on the cardiovascular risk factors examined.

Hopper et al. (33) included RCTs where ω-3 intake or advice was randomly allocated and unconfounded, and study duration was at least six months. Cohorts were included when followed-up for at least six months and ω-3 intake estimated. Forty-eight randomised controlled trials (36,913 participants) and 41 cohort analyses were included. Pooled trial results did not show a reduction in the risk of total mortality or combined cardiovascular events in subjects taking additional ω-3 fats. While reducing heterogeneity, sensitivity analysis confirmed the lack of any significant effect of ω-3 fats. Neither RCTs nor cohorts suggested increased RR of cancers with higher ω-3 intake but estimates were unreliable so a clinically important effect could not be excluded. Reviewers’ conclusions were that: i) it is not clear that dietary or supplemental ω-3 fats alter total mortality, combined cardiovascular events or cancers in people with, or at high risk of, cardiovascular disease or in the general population; ii) there is no evidence to advise people to stop taking rich sources of ω-3 fats, but further high quality trials are needed to confirm suggestions of a protective effect of ω-3 fats on cardiovascular health; iii) there is no clear evidence that ω-3 fats differ in effectiveness according to fish or plant sources, dietary or supplemental sources, dose or presence of placebo.

A meta-analysis of cohort studies was conducted by He et al. (34) to examine the association between fish intake and CHD mortality. Compared with those who never consumed fish or ate fish less than once per month, individuals with a higher intake of fish had lower CHD mortality. The pooled multivariate RRs for CHD mortality were 0.85 (95% CI: 0.76 to 0.96) for fish intake once per week, 0.77 (95% CI: 0.66 to 0.89) for 2–4 times per week, and 0.62 (95% CI, 0.46 to 0.82) for five or more times per week. Each 20-g/day increase in fish intake was related to a 7% lower risk of CHD mortality (p for trend=0.03).

Studer et al. (35) carried out a systematic search of randomised controlled trials, in which any lipid-lowering intervention has been compared with placebo or to usual diet with respect to mortality. Outcome measures were mortality from all, cardiac, and non-cardiovascular causes (1). A total of 97 studies met eligibility criteria, with 137,140 individuals in intervention and 138,976 individuals in control groups. The selection of the trials was oriented towards comparison of individual drugs to placebo or usual care. Based on pharmacological characteristics, the trials were divided into statin, fibrate, resin, niacin, omega-3 PUFA, and dietary intervention groups. The ω-3 fat group included 14 trials with nine trials on secondary cardiovascular disease prevention. The average relative reduction in total cholesterol was highest in the statin group and lowest in the ω-3 group. Compared with control groups, risk ratios for overall mortality were 0.87 for statins (95% CI: 0.81–0.94), 1.00 for fibrates (95% CI: 0.91–1.11), 0.84 for resins...
(95% CI: 0.66–1.08), 0.96 for niacin (95% CI: 0.86–1.08), 0.77 for ω-3 fatty acids (95% CI: 0.63–0.94), and 0.97 for diet (95% CI: 0.91–1.04). Thus, the risk ratios for overall mortality were not correlated with reductions in cholesterol level. Compared with control groups, risk ratios for cardiac mortality indicated benefit from statins (0.78; 95% CI: 0.72–0.84), resins (0.70; 95% CI: 0.50–0.99) and ω-3 fatty acids (0.68; 95% CI: 0.52–0.90). Risk ratios for non-cardiovascular mortality of any intervention, indicated no association when compared with control groups, with the exception of fibrates (1.13; 95% CI: 1.01–1.27). Their conclusion was that statins and ω-3 fatty acids are the most favorable lipid-lowering interventions with reduced risks of overall and cardiac mortality. The estimated number to treat for one year in this group was 140 patients for secondary prevention to prevent one death, whereas for the statin group, the number to treat was 248 patients for secondary prevention. In primary prevention (with a mortality rate of below 1% per year) the number to treat was 855 patients to prevent one death. Similar to JELIS, this review also concluded that the benefits of ω-3 fats were not related to reduction in the cholesterol level.

The effect of fish oil on heart rate (HR), a major risk factor for sudden death, was calculated by Mozaffarian (36) in a meta-analysis of randomised, double-blind, placebo-controlled trials of fish oil in humans. Predefined stratified meta-analyses and meta-regression were used to explore potential heterogeneity. They concluded that in randomised controlled trials in humans, fish oil reduces HR, particularly in those with higher baseline HR or longer treatment duration. These findings provide firm evidence that fish oil consumption directly or indirectly affects cardiac electrophysiology in humans.

To review systematically the evidence for an effect of long chain and shorter chain ω-3 fatty acids on total mortality, cardiovascular events, and cancer, Hopper et al. (37) analysed RCTs of ω-3 intake in adults with or without risk factors for cardiovascular disease. The authors concluded that long chain and shorter chain ω-3 fats do not have a clear effect on total mortality, combined cardiovascular events, or cancer.

At variance with all previous meta-analyses, this controversial meta-analysis included the very large negative clinical trial by Burr et al. (20) that appeared to strongly influence the overall effect and statistical significance of the pooled clinical trials.

In addition to oils, fish contains also contaminants (e.g. dioxins, methyl-mercury; polychlorinated biphenyls) that might hamper its advantages (risk for cardiovascular and neurologic outcomes in adults, risk of cancer etc.). Two systemic reviews/meta-analyses (38, 39) have been carried out to address the issue. To determine estimates of the effect of ω-3 fatty acids on cancer risk in prospective cohort studies, MacLean et al. (38) screened a total of 38 articles with a description of effects of consumption of ω-3 fatty acids on tumour incidence, prospective cohort study design, human study population; and description of effect of ω-3 among groups with different levels of exposure in the cohort were included. The high degree of heterogeneity across these studies precluded pooling of data. For breast cancer, one significant estimate was for increased risk (incidence risk ratio [IRR]: 1.47; 95% CI: 1.10–1.98) and three were for decreased risk (RR: 0.68–0.72); seven other estimates did not show a significant association. For colo-rectal cancer, there was one estimate of decreased risk (RR: 0.49; 95% CI: 0.27–0.89) and 17 estimates without association. For lung cancer, one of the significant associations was for increased risk (IRR: 3.0; 95% CI: 1.2–7.3), the other was for decreased risk (RR: 0.32; 95% CI: 0.13–0.76), and four other estimates were not significant. For prostate cancer, there was one estimate of decreased risk (RR: 0.43; 95% CI: 0.22–0.83) and one of increased risk (RR: 1.98; 95% CI: 1.34–2.93) for advanced prostate cancer; 15 other estimates did not show a significant association. The study that assessed skin cancer found an increased risk (RR: 1.13; 95% CI: 1.01–1.27). No significant associations between ω-3 fatty acid consumption and cancer incidence were found for aerodigestive cancer, bladder cancer, lymphoma, ovarian cancer, pancreatic cancer, or stomach cancer. Thus, a large body of literature spanning numerous cohorts from many countries and with different demographic characteristics does not provide evidence to suggest a significant association between ω-3 fatty acids and cancer incidence. Dietary supplementation with ω-3 fatty acids is unlikely to prevent cancer.

Mozaffarian et al. (39) identified reports published through April 2006 evaluating intake of fish or fish oil and cardiovascular risk; effects of methylmercury and fish oil on early neurodevelopment; risks of methylmercury for cardiovascular and neurologic outcomes in adults, and health risks of dioxins and polychlorinated biphenyls in fish.

A modest consumption of fish (e.g. 1–2 servings/week), especially of species higher in EPA and DHA, reduces risk of coronary death by 36% (p<0.001) and total mortality by 17% (p=0.046) and may favourably affect other clinical outcomes. Intake of 250 mg/day of EPA and DHA appears sufficient for primary prevention. DHA appeared beneficial for, and low-level methylmercury may adversely affect, early neurodevelopment. Women of childbearing age and nursing mothers should consume two seafood servings/week, limiting intake of selected species. Health effects of low-level methylmercury in adults are not clearly established; methylmercury may modestly decrease the cardiovascular benefits of fish intake. A variety of seafood should be consumed; individuals with very high consumption (≥25 servings/week) should limit the intake of species highest in mercury levels. In conclusion, the benefits of fish intake exceed the potential risks. For women of childbearing age, benefits of modest fish intake, excepting a few selected species, also outweigh risks.

Since none of the three trials on ω-3 fatty acids supplementations and prevention of arrhythmias convincingly showed whether or not supplementation with ω-3 fatty acids has preventive effects in ICD patients, a meta-analysis was carried in which the results of these three trials were combined to assess the effect of fish oil on VT in the total group of ICD patients and in subgroups with different disease history (40). The authors concluded that the data available do not support a protective effect of ω-3 fatty acids from fish oil on cardiac arrhythmia in all patients with an ICD.
The biological plausibility (potential mechanisms) of the benefits of ω-3 fatty acids use in cardioprotection

It has long been known that the biological effects of ω-3 fatty acids, some of which are related to DHA and EPA enrichment of membrane phospholipids (41), include lowering of monocyte adhesion to endothelial cells and of plasma triglycerides; LTβ4, PDGF, and VLDL-cholesterol; enhancement of HDL-cholesterol and of membrane fluidity (42). By analysing the strengths of the findings and how the meta-analyses agree with the individuals trials, the following lines of evidence emerge.

- **Diary dietary and non-dietary intake of ω-3 fatty acids is inversely associated with fatal CHD:** it reduces overall mortality, mortality due to MI, and sudden death in patients with CHD;
- **Among patients with implantable cardioverter defibrillators, there is evidence that ω-3 fatty acids do not reduce the risk of ventricular tachycardia/ventricular fibrillation and may actually be pro-arrhythmic;**
- **It is possible that ω-3 fatty acids can have anti-arrhythmic or pro-arrhythmic effects depending on the origins of arrhythmias;**
- **Fish oil consumption directly or indirectly affects cardiac electrophysiology.** There is good evidence that fish oil reduces HR, a major risk factor for sudden death. This is particularly relevant in individuals with higher baseline HR or longer treatment duration;
- **The consumption of ω-3 fatty acids leads to a large (10–33%), consistent decrease of triglyceride levels.** The effect is dose-dependent, larger in studies with higher mean baseline triglyceride levels, and consistent in different populations (healthy people, people with dyslipidaemia, diabetes, or known cardiovascular risk factors). The effect of ω-3 fatty acids on serum lipids other than triglycerides is weak (up to a 6% increase in HDL). The benefits of ω-3 fatty acids are not related to reduction in the cholesterol level nor are they well explained by the effects on major cardiovascular risk factors;
- **ω-3 fatty fatty acids and statins are the most favorable lipid-lowering interventions, with reduced risks of overall and cardiac mortality;**
- **Outcomes for which a small benefit of ω-3 fatty acids is found, include blood pressure (about 2 mm Hg reduction), re-stenosis rates after coronary angioplasty (14% reduction), and exercise tolerance testing.**

Four major lines of evidence support the plausibility of these concepts.

- **Antiarrhythmic/antifibrillatory effects.** In almost 50% of cases, sudden death is preceded by life-threatening cardiac arrhythmias (43). In *vitro* and *in vivo* observations imply that the anti-arrhythmic effect ω-3 fatty acids is related to the modulation of the Na⁺ and Ca²⁺ currents in the myocyte sarcolemma, electrical stabilisation of cardiomyocytes, enhanced myocardial efficiency, and increased resistance to reperfusion arrhythmias (44). In the GISSI Prevenzione trial (14), the supplementation of low/intermediate dose ω-3 fatty acids (810 mg/day) given to stable coronary artery disease (CAD) patients decreased resting heart rate, increased post-exercise heart rate recovery, and increased beat-to-beat heart rate variability. These changes have been interpreted to be due to improved autonomic sympathovagal balance (45, 46). In keeping with this, ω-3 fatty acids inhibit voltage-gated sodium channels in cardiomyocytes, resulting in a longer relative refractory period and an increased threshold voltage required for depolarization (47). ω-3 fatty acids also maintain the integrity of L-type calcium channels, preventing cytosolic calcium overload during periods of ischaemic stress (48–50). Studies in patients undergoing heart transplants suggest that ω-3 fatty acids can reduce heart rate independently of vagal activation (51).

- **Effects on endothelial function, autonomic tone and blood pressure.** In 14 healthy volunteers, a one-month supplementation of a preparation of EPA and DHA superimposable to that employed in the GISSI Prevenzione study, in parallel with changes in the plasma and platelet content of EPA and DHA, caused an impaired platelet aggregation in response to collagen or ADP that was independent of thromboxane biosynthesis. Such impaired aggregation correlated (p=0.036 and 0.068, respectively) with changes in the intracellular pH (pHi) of the Na⁺/H⁺ reverse transport (52). In addition to platelet function, the latter mechanism is important as to lymphocyte function and blood pressure control (53, 54). As recently stressed in a comprehensive review on the issue (55), ω-3 fatty acids are capable of reducing blood pressure (45, 46), to improve arterial and endothelial function (57), and to favourably affect the autonomic tone of the vessels (45, 57). In a meta-regression analysis of 22 double-blind randomised trials on blood pressure response to fish oil supplementation (58), consumption of ~4.0 g/day of ω-3 fatty acids was associated with a significant 1.7– and 1.5-mm Hg reduction in systolic and diastolic blood pressure. Such reductions were maximal in older patients and in those with higher blood pressures. A 2 mm Hg reduction in blood pressure yields to a 4% reduction in mortality due to CAD (59). Changes in cell membrane composition that follow the supplementation of ω-3 fatty acids are thought to be essential to achieve these effects, and DHA is reported to be more important than EPA in this respect. Although higher levels of DHA than of EPA are present in membrane phospholipids (60), data from JELIS challenge this formulation. Moreover, membranes typically contain 10 times as much AA as EPA (52), and EPA is a weaker substrate than AA for the production of cyclooxygenase- and lipoperoxidase-derived eicosanoids (60). Changes in the lipid composition of the cellular membranes that occur following a dietary supplementation with EPA+DHA are likely to alter the activity of membrane-bound proteins (receptors, ion channels, etc), thus causing vascular effects (55).

- **Antithrombotic and antiinflammatory effects.** In RCTs in secondary prevention of CHD studies, a large proportion of individuals, in addition to ω-3 fatty acids, was simultaneously receiving aspirin (> 80% in the GISSI Prevenzione). Since aspirin impairs...
thromboxane formation, a major mechanism of platelet activation, and chronic ω-3 fatty acids supplementation impair ADP-induced aggregation (52), another important mechanism of platelet activation, sudden death prevention may well be the result of a more intensive anti-platelet treatment. Studies in settings of coronary ischaemia (acute coronary syndrome, coronary stenting etc) where the synergistic effect of combinations of antiplatelet agents (e.g. aspirin + clopidogrel) with different antiplatelet mechanisms greatly reduced acute coronary deaths, support this formulation. When administered to obese people, high-dose ω-3 fatty acids (1.8 g/day of EPA) increased the level of adiponectin that, besides improving insulin sensitivity, reduces inflammation indices (61). On the other hand, very high-dose ω-3 fatty acids (8.0 g/day) have been shown to have anti-inflammatory effects in patients with HF (62). These data imply that, in addition to the well known anti-platelet effects (52, 63), the search for a biological plausibility has to take into consideration the anti-inflammatory properties of ω-3 fatty acids. ω-3 fatty acids have been shown to suppress the production of proinflammatory cytokines such as interleukin-6, interleukin-1β, and tumour necrosis factor-α (64–67). In a cross-sectional study of 5,677 men and women from the Multi-Ethnic Study of Atherosclerosis (MESA) cohort, including African Americans, Caucasians, Chinese, and Hispanics aged 45 to 84 years and free of clinical cardiovascular disease, He et al. (68) have documented the ability of long-chain ω-3 fatty acid intake (as assessed by a self-administered food frequency questionnaire) to affect variables reflecting low levels of inflammation and endothelial activation. The intake was inversely associated with plasma concentrations of interleukin-6 (p = 0.01) and of matrix metalloproteinase-3 (p = 0.03). Such association was independent of age, body mass index, physical activity, smoking, alcohol consumption, and dietary variables. Non-fried fish consumption was inversely related to C-reactive protein (p = 0.045) and interleukin-6 (p < 0.01), and after adjustment for potential confounders, fried fish consumption was inversely related to soluble intercellular adhesion molecule-1 (p < 0.01). However, the ability of ω-3 fatty acids to consistently lower C-reactive protein levels has been challenged (69). In addition, other studies with ω-3 fatty acids have not found significant changes in pro-thrombotic markers (70, 71).

- **Lipid lowering effects.** When triglycerides are raised, the cardiovascular risk from high serum cholesterol or low HDL cholesterol is enhanced. Some of the cardioprotective effects of high-dose ω-3 fatty acids is likely to be due to their favorable effects on the lipid profile. In addition to the direct ability to lower plasma triglyceride levels, relatively high (3.4 g/day) amounts of ω-3 fatty acids may enhance the effects of simvastatin therapy, by further lowering (~30%) triglyceride levels and VLDL cholesterol levels (~9.0%), with a significant increase in HDL levels (72). As to LDL cholesterol, the effect of high dose ω-3 fatty acids is largely dependent on the baseline lipid profile: in hypercholesterolaemic subjects (e.g. those randomised in the JELIS study), LDL is reduced by ~10%; in moderately elevated and highly elevated baseline triglyceride levels, it is increased by ~10–30% (73, 74). Lp-PLA2 is an emerging independent risk factor for cardiovascular disease. Following oxidation of the LDL particle, Lp-PLA2 cleaves the oxidised phosphatidylcholine to lysophosphatidylcholine and oxidised free fatty acids, both proinflammatory compounds. Pedersen et al. (75) have evaluated the effect of marine ω-3 fatty acids on plasma Lp-PLA2 levels in 60 healthy subjects randomised to a moderate dose (2 g) of ω-3 fatty acids, a high dose (6.6 g) of ω-3 fatty acids or olive oil (control) daily for 12 weeks. Plasma Lp-PLA2 was measured at baseline and after the interventions. In the report, the authors called attention to the ability of ω-3 fatty acids to exert antithrombotic effects by counteracting pro-atherosclerotic leukocyte activation and pro-inflammatory effects elicited by Lp-PLA2, which, in turn may hamper plaque instability suggested to be promoted by Lp-PLA2 (76, 77). Hypertriglyceridaemia is the most common hyperlipidaemia found survivors of MI. The concepts that i) raised triglycerides are an independent risk factor for CAD (78), and ii) that they act synergistically with other lipids and lipoproteins (mostly, lipoprotein-transporting triglycerides) to create high-risk individuals (79), have been confirmed and extended. In a meta-analysis of 17 population-based studies, abnormally high triglycerides are associated with a 30% increase in cardiovascular disease in men and with a 75% increase in women (80). Despite the unsolved issue whether or not triglyceride concentrations should be measured in a fasting state (81), these data support the concept that triglyceride levels >1.7 mM are associated with raised cardiovascular risk (82). On the other hand, according to the results of secondary-prevention trials of CAD events (83–86), the efficacy of ω-3 fatty acids for all-cause mortality may not only involve triglyceride lowering.

**Perspectives**

In the era of poly-pills for CHD prevention, drugs with multifaceted mechanisms of action should be taken into serious consideration. The additional benefits of ω-3 fatty acids over and above the usual GiSSI strategy do not include the lowering of total or LDL cholesterol. Moreover, during the last decade, the interest for the antithrombotic hypothesis of ω-3 fatty acids has progressively waned. In contrast, although the mechanism by which triglycerides promote atherogenicity is difficult to be split from its synergistic effects on lipids, lipoprotein and other cardiovascular variables, the triglyceride lowering and anti-arrhythmic effects of ω-3 fatty acids appear to be major directions to be pursued. The implications of this possibility are discussed below.

- The metabolic syndrome is a clinical situation in which raised plasma triglycerides cluster together with other atherogenic dyslipidaemias, visceral fat accumulation, different degrees of hypertension, abnormal glucose metabolism, and pro-thrombotic and pro-inflammatory conditions (reviewed in [89, 90]). Such patients are at a higher than normal risk of myocardial ischaemia. In patients with hypertriglyceridaemia and abnormal...
glucose tolerance, ω-3 fatty acid supplementation does not lead to increased risk of diabetes (91). In overweight and obese adults, ω-3 fatty acid supplementation improves insulin sensitivity (92). The antiarrhythmic action of ω-3 fatty acids may well involve a hyperinsulinaemic effect in patients with MI (1).

- Non-alcoholic fatty liver disease (NAFLD) may be regarded as the hepatic expression of the metabolic syndrome: the more facets of the metabolic syndrome are present, the greater the chance of developing NAFLD (93, 94). NAFLD encompasses isolated hepatic steatosis, non-alcoholic steato-hepatitis and cirrhosis: it is characterised by the pathological accumulation of fat in the liver when no other explanatory disease is present (93, 94). NAFLD it is the most common cause of liver disease in the US, and accounts for 11% of referrals to hepatology services (93, 94). NAFLD predicts the development of other features of the metabolic syndrome; it is independently associated with a raised risk of vascular events and, in the NHANES-III population-based study, with increased mortality (95). Inasmuch NAFLD affects 10–35% of the adult population worldwide, there is no consensus on its treatment (96). ω-3 fatty acids are important regulators of hepatic gene transcription (93). Heterozygosity for the haemochromatosis gene is common in NAFLD; polymorphisms in the genes coding for the nuclear envelope protein lamin A as well as for PPAR-γ have been identified in partial lipodystrophies (reviewed in [93, 96]). Animal studies show that ω-3 fatty acids reduce hepatic steatosis, improve insulin sensitivity and reduce markers of inflammation, in all major events in NAFLD development (93, 94, 96). In view of this, ω-3 fatty acids have recently been suggested as a direction to be pursued to define appropriate strategies of treatment for NAFLD. A critical appraisal of the literature (96) shows that, in spite of inherent significant design limitations (sample size; follow-up etc.), clinical trials in human subjects confirm experimental findings, and argue for ω-3 fatty acids as being a promising treatment for NAFLD. Such direction needs to be tested in ad hoc randomised placebo-controlled trials.

- ω-3 fatty acids reduce HR, a major risk factor for sudden death. Low HR variability is associated with an abnormally high morbidity and mortality in post-MI patients (1). ω-3 fatty acids exert a protective effect against fatal ventricular arrhythmias, particularly in post-MI patients, and against atrial fibrillation (AF) (14, 36). In addition to post-MI, AF is the most common complication after coronary artery bypass surgery (98). Presently, it is unclear whether ω-3 fatty acids have a direct effect on the heart. Little is known about the influence of ω-3 fatty acids supplements on energy homeostasis in post-MI patients, where the balance between glucose and non-esterified fatty acids may be crucial for the vitality of the myocardium (1, 99). The prevention of the adverse effects of fatty acid toxicity in the ischemic myocardium (free radical formation) may be a direction to be pursued. In a dog model (100), infusion of ω-3 fatty acids prevents ischaemia-induced sudden cardiac death by preventing ventricular fibrillation. The possibility of anti-arrhythmic and pro-arrhythmic effects ω-3 fatty acids depending on the origins of arrhythmias, needs to be evaluated in ad hoc trials.

- Seventy five years ago, long chain ω-3 fatty acids were added to the list of essential nutrients. Presently, their use in childhood, lactation and pregnancy is established (22). In individuals eating low amounts of fish, the optimal target EPA + DHA consumption has been suggested (101) to be at least 500 mg/day for individuals without underlying overt CV disease and at least 800 to 1,000 mg/day for individuals with CHD and HF. In spite of this, presently, there is no evidence as to whether concentrated preparations of ω-3 fatty acids are interchangeable with individual preparations of DHA or EPA. Likewise, optimal dosing, duration and the relative ratio of DHA and EPA ω-3 PUFA that provides maximal protection in primary and secondary vascular disease are little known.

References


69. Madsen T, Schmidt EB, Christensen JH. The effect of n-3 fatty acids on C-reactive protein levels in patients with chronic renal failure. J Ren Nutr 2007; 17: 258–263.
77. Weintraub HS. Identifying the vulnerable patient with rupture-prone plaque. Am J Cardiol 2008; 101: 3F–10F.
82. British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association. JBS 2; Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91 (Suppl 5): v1–v5.
97. Masterton GS, Plevris JN, Hayes PC. Review article: omega-3 fatty acids – a promising novel therapy for non-alcoholic fatty liver disease. Aliment Pharma
col Ther 2010; 31: 679–692.